July 6, 2018

Please reload

Recent Posts

FDA Comments on Recently Released Rare Disease Guidance for Industry

September 16, 2015

Jonathan Goldsmith, M.D., F.A.C.P., FDA’s Associate Director, Rare Diseases Program, Center for Drug Evaluation and Research, comments on the recently...

Please reload

Featured Posts

Patagonia Completes Enrollment in Phase IIa Study

December 29, 2017

Patagonia is excited to announce that we have completed enrollment in our Phase IIa study for congenital ichthyosis.  Ichthyosis is a family of genetic skin disorders characterized by dry, scaling skin that may be thickened or very thin. It affects people of all ages, races and gender. The disease usually presents at birth, or within the first year, and will continue to affect the patient throughout their lifetime.¹


This study was conducted at 5 sites throughout the United States and investigated the potential of PAT-001 in the X-Linked and Lamellar subtypes.  We would like to thank our investigators and the team at FIRST (http://www.firstskinfoundation.org/) for their support throughout this study.  


If you are interested in participating in a future study, please visit www.ichthyosistrial.com. 


¹ FIRST (Foundation for Ichthyosis and Related Skin Types)





Please reload

Patagonia Pharmaceuticals, LLC

50 Tice Blvd, Suite A26

Woodcliff Lake, NJ 07677

For more info: info@patagoniarx.com

© 2019 by Patagonia Pharmaceuticals, LLC